Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 811-818

  Jeong, Woojin ^a   Kim, Sang Bae ^b   Sohn, Bo Hwa ^b   Park, Yun Yong ^b   Park, Eun Sung ^c   Kim, Sang Cheol ^d   Kim, Sung Soo ^e   Johnson, Randy L ^b   Birrer, Michael ^f   Bowtell, David S L ^g   Mills, Gordon B ^b   Sood, Anil ^b   Lee, Ju Seog ^b,e  

^a Ewha Womans University   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

DNA microarrays; Ovarian cancer; Prognosis; Taxane; YAP1

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR YAP1; ANTINEOPLASTIC AGENT; HIPPO PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAXANE; TAXOID; YAP1 (YES ASSOCIATED) PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL (TOPIC); SINGLE DRUG DOSE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; BIOSYNTHESIS; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; DNA MICROARRAYS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YAP1; YOUNG ADULT;

DNA MICROARRAYS; OVARIAN CANCER; PROGNOSIS; TAXANE; YAP1;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLUSTER ANALYSIS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TAXOIDS; YOUNG ADULT;

EID: 84897067669     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X and Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell 5: 19-24, 2004.
3. Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
4. Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell 124: 267-273, 2006.
5. Pan D: Hippo signaling in organ size control. Genes Dev 21: 886-897, 2007.
6. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS and Johnson RL: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 107: 1437-1442, 2010.
7. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, Wang CY, Gao B, Jiang J and Yang Y: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 107: 1431-1436, 2010.
8. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J and Bardeesy N: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438, 2009.
9. Zhao B, Lei Q and Guan KL: Mst out and HCC in. Cancer Cell 16: 363-364, 2009.
10. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DD and Harvey KF: The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30: 2810-2822, 2011.
11. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of Yes-associated protein in common solid tumors. Hum Pathol 39: 1582-1589, 2008.
12. Zhang J, Smolen GA and Haber DA: Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 68: 2789-2794, 2008.
13. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A and Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
15. Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, Nicke B, Downward J, Swanton C, Bell SD, Earl HM, Laskey RA, Caldas C and Brenton JD: The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12: 514-527, 2007.
16. Simon R, Lam A, Li MC, Ngan M, Menenzes S and Zhao Y: Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Inform 4: 11-17, 2007.
17. Wright GW and Simon RM: A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448-2455, 2003.
18. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
19. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ and Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676, 2004.
20. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK and Thorgeirsson SS: Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306-1311, 2004.
21. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T and Thorgeirsson SS: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12: 410-416, 2006.
22. Radmacher MD, McShane LM and Simon R: A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505-511, 2002.
23. Saucedo LJ and Edgar BA: Filling out the Hippo pathway. Nat Rev Mol Cell Biol 8: 613-621, 2007.
24. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC and Guan KL: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22: 1962-1971, 2008.
25. Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo SC, Kim KH, Yoon MS, Suh DS and Kim JH: TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem 32: 253-263, 2013.
26. Cai H and Xu Y: The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 11: 31-11, 2013.
27. St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG, Parlow AF, McGrath J and Xu T: Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 21: 182-186, 1999.
28. Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10: 211-224, 2013.